Contributions
Abstract: EP1588
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 24 Neuropsychology
Background: Cognitive impairment occurs frequently in the patients with multiple sclerosis (MS). However, the accuracy rate of subjective cognitive complaints for predicting of abnormal objective cognitive performance is lacking.
Objectives: To investigate the relationship between subjective cognitive complaints assessed by the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) and objective cognitive performance evaluated by the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).
Methods: A total of 1052 patients (70% females, at baseline: mean age: 38.1±8.8; mean disease duration: 9.6±7.1) after the first demyelinating event suggestive of MS or with clinically definitive MS were included in this 2-years longitudinal study. The MSNQ, the BICAMS battery and the Beck Depression Inventory (BDI) were evaluated at baseline and at 24 months. Pearson´s and Spearman´s correlation analyses were performed to evaluate the relationships among absolute values of the MSNQ, the BICAMS subtests and the BDI score. Sensitivity, specificity, accuracy and positive predictive value were used to assess agreement between the subjective and objective screening methods.
Results: At baseline, we observed a weak negative correlation (r=-0.273 to -0.134; p< 0.001) between absolute values of the MSNQ and the BICAMS subtests. The abnormal MSNQ (cut-off value >24) at baseline identified patients with the abnormal BICAMS (≥1 abnormal subtest) at baseline with 69% accuracy (sensitivity=33%, specificity=83%, positive predictive value [PPV]=41%). The MSNQ was also associated with the BDI (r=0.540; p< 0.001). We observed a weak negative correlation between absolute values of the MSNQ at baseline and the BICAMS subtests at 24 months (r=-0.259 to -0.117; p< 0.001). The abnormal MSNQ at baseline identified patients with the abnormal BICAMS at 24 months with 64% accuracy (sensitivity=30%, specificity=82%, PPV=46%).
Conclusion: Subjective evaluation of cognitive performance assessed by the MSNQ predicted the abnormal outcome of objective cognitive screening by the BICAMS with only 64-69% accuracy. On the other hand, the abnormal MSNQ was associated with abnormal cognitive screening with a relatively high specificity (82-83%). MSNQ is not suitable cognitive screening tool due to its low sensitivity (30-33%), however, subjective cognitive complaints of MS patients need to be taken seriously, because they are often associated with cognitive impairment or depressive symptoms.
Disclosure: The project was supported by the Czech Ministry of Education project Progres Q27/LF1.
Lucie Kadrnozkova received compensation for conference travel from Roche.
Jiri Motyl: nothing to disclose.
Jana Blahova Dusankova: nothing to disclose.
Michaela Andelova has received travel and conference fees support from Novartis and Biogen Idec.
Barbora Benova received compensation for travelling and conference fees from Novartis and Sanofi Genzyme and Biogen Idec.
Klara Novotna received compensation for travel and speaker honoraria from Merck, Novartis and Teva
Karolina Kucerova: nothing to disclose.
Jana Lizrova Preiningerova has received speaker and consulting fees from Biogen,
Novartis, and Teva.
Eva Havrdova received speaker honoraria and consultant fees from Biogen Idec, Merck Serono, Novartis, Genzyme and Teva, as well as support for research activities from Biogen Idec and Merck Serono.
Dana Horakova received compensation for travel, speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche, and Teva, as well as support for research activities from Biogen Idec.
Tomas Uher received financial support for conference travel and honoraria from Biogen Idec, Novartis, Genzyme, Roche and Merck Serono, as well as support for research activities from Biogen Idec.
Abstract: EP1588
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 24 Neuropsychology
Background: Cognitive impairment occurs frequently in the patients with multiple sclerosis (MS). However, the accuracy rate of subjective cognitive complaints for predicting of abnormal objective cognitive performance is lacking.
Objectives: To investigate the relationship between subjective cognitive complaints assessed by the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) and objective cognitive performance evaluated by the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).
Methods: A total of 1052 patients (70% females, at baseline: mean age: 38.1±8.8; mean disease duration: 9.6±7.1) after the first demyelinating event suggestive of MS or with clinically definitive MS were included in this 2-years longitudinal study. The MSNQ, the BICAMS battery and the Beck Depression Inventory (BDI) were evaluated at baseline and at 24 months. Pearson´s and Spearman´s correlation analyses were performed to evaluate the relationships among absolute values of the MSNQ, the BICAMS subtests and the BDI score. Sensitivity, specificity, accuracy and positive predictive value were used to assess agreement between the subjective and objective screening methods.
Results: At baseline, we observed a weak negative correlation (r=-0.273 to -0.134; p< 0.001) between absolute values of the MSNQ and the BICAMS subtests. The abnormal MSNQ (cut-off value >24) at baseline identified patients with the abnormal BICAMS (≥1 abnormal subtest) at baseline with 69% accuracy (sensitivity=33%, specificity=83%, positive predictive value [PPV]=41%). The MSNQ was also associated with the BDI (r=0.540; p< 0.001). We observed a weak negative correlation between absolute values of the MSNQ at baseline and the BICAMS subtests at 24 months (r=-0.259 to -0.117; p< 0.001). The abnormal MSNQ at baseline identified patients with the abnormal BICAMS at 24 months with 64% accuracy (sensitivity=30%, specificity=82%, PPV=46%).
Conclusion: Subjective evaluation of cognitive performance assessed by the MSNQ predicted the abnormal outcome of objective cognitive screening by the BICAMS with only 64-69% accuracy. On the other hand, the abnormal MSNQ was associated with abnormal cognitive screening with a relatively high specificity (82-83%). MSNQ is not suitable cognitive screening tool due to its low sensitivity (30-33%), however, subjective cognitive complaints of MS patients need to be taken seriously, because they are often associated with cognitive impairment or depressive symptoms.
Disclosure: The project was supported by the Czech Ministry of Education project Progres Q27/LF1.
Lucie Kadrnozkova received compensation for conference travel from Roche.
Jiri Motyl: nothing to disclose.
Jana Blahova Dusankova: nothing to disclose.
Michaela Andelova has received travel and conference fees support from Novartis and Biogen Idec.
Barbora Benova received compensation for travelling and conference fees from Novartis and Sanofi Genzyme and Biogen Idec.
Klara Novotna received compensation for travel and speaker honoraria from Merck, Novartis and Teva
Karolina Kucerova: nothing to disclose.
Jana Lizrova Preiningerova has received speaker and consulting fees from Biogen,
Novartis, and Teva.
Eva Havrdova received speaker honoraria and consultant fees from Biogen Idec, Merck Serono, Novartis, Genzyme and Teva, as well as support for research activities from Biogen Idec and Merck Serono.
Dana Horakova received compensation for travel, speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche, and Teva, as well as support for research activities from Biogen Idec.
Tomas Uher received financial support for conference travel and honoraria from Biogen Idec, Novartis, Genzyme, Roche and Merck Serono, as well as support for research activities from Biogen Idec.